TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \>=18 years of age;~* recipients of solid organ(s) transplant;~* virologic and clinical evidence of CMV disease after transplantation;~* patients of childbearing potential must be prepared to use effective contraception throughout, and for 90 days after the end of the study.~Exclusion Criteria:~* life-threatening CMV disease according to the investigator's judgment;~* pregnant or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has documented HIV-1 infection~* Treatment with an Antiretroviral regimen (containing at least 2 NRTIs in combination with at least 1 NNRTI and/or 1 PI) for at least 12 weeks~* Plasma HIV-1 RNA \>1000 copies/mL~* General medical condition does not interfere with the assessments and the completion of the trial~Exclusion Criteria:~* Patients for whom an investigational Antiretroviral is part of the current regimen, with the following exceptions if applicable (depending on local regulatory approval)~* tenofovir, emtricitabine, atazanavir, fosamprenavir~* Previous or current use of lopinavir, enfuvirtide (T-20), tipranavir and TMC114~* Life expectancy of less than 6 months~* Pregnant or breast-feeding~* Females of childbearing potential not willing to use effective non-hormonal birth control methods or not willing to continue practicing these birth control methods for at least 14 days after the end of the treatment period~* Patients with significantly decreased liver function or decompensation, irrespective of liver enzyme levels~* Participation in other investigational trials without prior approval of the sponsor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 002 (Type: EXPERIMENTAL): LPV/rtv One 400mg LPV tablet twice daily with 100mg RTV
- 001 (Type: EXPERIMENTAL): TMC114/rtv Two 300mg TMC114 tablets twice daily with 100mg RTV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* BMI (Body Mass Index): 20-30 kg/m\^2~* Body weight: 60-110 kg~* Normal ECG (electrocardiogram)~Exclusion Criteria:~* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method. Women of child-bearing potential must use an effective method of birth control for the duration of the trial and for 5 weeks following the last dose of semaglutide. Only highly effective methods of birth control are accepted (i.e. one that results in less than 1% per year failure rate when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices), or sexual abstinence or vasectomised partner~* Any clinically significant disease history, in the opinion of the investigator, or systemic or organ~* History of seizures, epilepsy, syncope, cardiac arrest, cardiac arrhythmia or Torsades de Pointes, A-V (Atrioventricular) block or structural heart disease~* Family history of long QT (Interval in the ECG: from the start of the QRS complex to the end) syndrome (either objectively diagnosed or suggested by sudden death due to cardiac causes before the age of 50 of a 1st degree relative)~* Family history of sudden cardiac death before the age of 50 of a 1st degree relative~* Use of prescription or non-prescription systemic or topical medicinal products (except routine vitamins, acetylsalicylic acid, paracetamol and contraceptives) within 3 weeks (or within 5 halflives of the medicinal product, whichever is longest) prior to the first dosing of semaglutide~* Smoking, drug or alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1: semaglutide + moxifloxacin placebo (Type: EXPERIMENTAL): Subjects will receive a single dose of moxifloxacin placebo both before the start of semaglutide treatment and at the end of the semaglutide treatment.
- Arm 2A: (Type: ACTIVE_COMPARATOR): Semaglutide placebo + moxifloxacin/moxifloxacin placebo:~Subjects will receive moxifloxacin before the start of semaglutide placebo treatment and moxifloxacin placebo at the end of the semaglutide placebo treatment.
- Arm 2B: (Type: EXPERIMENTAL): Semaglutide placebo + moxifloxacin placebo/moxifloxacin:~Subjects will receive moxifloxacin placebo before the start of semaglutide placebo treatment and moxifloxacin at the end of the semaglutide placebo treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between 18 and 45 years of age, inclusive~* Healthy males and females with no clinically significant abnormalities identified by a detailed medical history~* Body mass index ≥ 19.0 kg/m2 and ≤ 31.0 kg/m2~Exclusion Criteria:~* Systolic blood pressure \> 130 mmHg or \< 90 mmHg measured after 10 minutes supine at the Screening Visit and Study Day 1~* Diastolic blood pressure \> 90 mmHg or \< 60 mmHg measured after 10 minutes supine at the Screening Visit and Study Day 1~* Heart rate \> 90 bpm or \< 50 bpm measured after 10 minutes supine at the Screening Visit and Study Day~* Known allergy or hypersensitivity to PSE

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- TR-701 FA with PSE (Type: EXPERIMENTAL): TR-701 FA 200 mg oral with PSE
- TR-701 FA Placebo with PSE (Type: PLACEBO_COMPARATOR): TR-701 FA Placebo 200 mg oral with PSE

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Competitive Carriage of Neisseria Spp(Lactamica 2)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Currently healthy~* Students and university employees from either Sheffield Hallam University or the University of Sheffield between the ages of 18 and 25yrs.~* Fully conversant in the English language~* Able to attend the full protocol timetable~Exclusion Criteria:~* Individuals who are Immunocompromised due to a medical condition~* Individuals taking immune modifying medications (not including inhaled steroids)~* Individuals in close contact with immunocompromised people including medical students with full time clinical attachments.~* Individuals who have an current infection~* Current Smokers~* People with an allergy to yeast extract.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Univeristy of Sheffield (Type: EXPERIMENTAL): lactamica
- Hallam University (Type: PLACEBO_COMPARATOR): Phosphate Buffered Saline (PBS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of cryptogenic ischemic stroke or TIA of presumed embolic infarction verified by a neurologist within 180 days prior to randomization~* Presence of Patent Foramen Ovale (PFO), as determined initially by positive bubble study utilizing transesophageal echocardiography (TEE), demonstrating spontaneous right-to-left shunting or right-to-left shunting during Valsalva maneuver.~* Absence of an identifiable source of thromboembolism in the systemic circulation~* No evidence of a hypercoagulable state~* Note: Additional Inclusion Criteria may apply~Exclusion Criteria:~* Other co-morbidities including, but not limited to, mural thrombus, dilated cardiomyopathy, atrial fibrillation/flutter, cardiac prosthetics (valves), mitral valve stenosis, aortic dissection, significant atherosclerosis, vasculitis, pre-existing neurologic disorders, multiple sclerosis, arteriovenous malformations, prior intracranial hemorrhage, severe central nervous system (CNS) disease, severe disability related to prior stroke, and autoimmune disorders that would increase the risk of mortality or morbidity above what is typical for the treatment~* Previous Myocardial Infarction~* Active infection that cannot be treated successfully prior to randomization~* Sensitivity or contraindication to all proposed medical treatments~* Pregnancy or intent on becoming pregnant through 24-months after randomization~* Indications outside the parameters accepted for placement of the GORE® HELEX® Septal Occluder / GORE® Septal Occluder, including extensive congenital cardiac anomalies and defect diameter estimated to be \> 18mm~* Atrial septal anatomy that is expected to necessitate placement of more than one GORE® HELEX® Septal Occluder / GORE® CARDIOFORM Septal Occluder~* Need for concomitant procedure(s) that may confound detection of adverse events related to device placement~* Note: Additional Exclusion Criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Medical Management (Type: ACTIVE_COMPARATOR): Antiplatelet medical therapy alone
- Device Closure (Type: EXPERIMENTAL): PFO closure with study septal occluder device plus antiplatelet medical therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
PATIENT INCLUSION CRITERIA:~* Male or female and aged 18 years or over;~* Clinical diagnosis of orthostatic hypotension associated with Primary Autonomic Failure (PD, MSA and PAF), Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Autonomic Neuropathies;~* A documented fall in systolic blood pressure of at least 20 mmHg, or in diastolic blood pressure of at least 10 mmHg, within 3 minutes after standing;~* Provide written informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care.~MAIN PATIENT EXCLUSION CRITERIA:~* Taking ephedrine or midodrine; Patients taking ephedrine or midodrine may enroll after a minimum 7 day washout period;~* Taking anti-hypertensive medication;~* Have a history of more than moderate alcohol consumption;~* Women who are pregnant or lactating;~* Have a history of closed angle glaucoma;~* Have pre-existing sustained severe hypertension (BP \> 180/110 mmHg in the sitting position);~* Have atrial fibrillation or, in the investigator's opinion, have any other significant cardiac arrhythmia;~* In the investigator's opinion, have any other significant systemic, hepatic, cardiac or renal illness;~* Have diabetes mellitus or insipidus;~* Have a known or suspected malignancy;~* Have known gastrointestinal illness or other gastrointestinal disorder that may, in the investigator's opinion, affect the absorption of study drug;~* In the investigator's opinion, have clinically significant abnormalities on clinical examination or laboratory testing;~* Have a serum creatinine level \> 130 µmol/L;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Droxidopa (Type: EXPERIMENTAL): Double-blind
- Placebo (Type: PLACEBO_COMPARATOR): Double-blind

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Efficacy Study of Primaquine and Methylene Blue

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Glucose-6-phosphate dehydrogenase (G6PD) normal defined by CareStart™ G6PD rapid diagnostic test (RDT) or the OSMMR2000 G6PD semi-qualitative test~* Absence of symptomatic falciparum malaria, defined by fever upon enrollment~* Presence of P. falciparum gametocytes on thick blood film at a density \>30 gametocytes/µL (i.e. ≥2 gametocytes recorded in the thick film against 500 white blood cells)~* No allergies to study drugs~* No self-reported use of antimalarial drugs over the past 7 days (as reported by the participant)~* Hemoglobin ≥ 10 g/dL~* Individuals weighing \<80 kg~* No evidence of severe or chronic disease~* Written, informed consent~Exclusion Criteria:~* Age \< 5 years or \> 50 years~* Female gender~* Blood thick film negative for sexual stages of malaria~* Previous reaction to study drugs/known allergy to study drugs~* Signs of severe malaria, including hyperparasitemia, defined as asexual parasitemia \> 100,000 parasites / µL)~* Signs of acute or chronic illness, including hepatitis~* Use of other medications (with the exception of paracetamol and/or aspirin)~* Consent not given

- Gender: MALE
- Minimum Age: 5 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- SP-AQ only (Type: ACTIVE_COMPARATOR): Subjects will receive sulphadoxine-pyrimethamine (SP) as single dose and administered in combination with amodiaquine (AQ), which will be given once daily for 3 days.
- SP-AQ plus PQ (Type: EXPERIMENTAL): Participants in this arm will receive SP-AQ in combination with a single low dose of primaquine at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
- DP only (Type: ACTIVE_COMPARATOR): Participants in this arm will be treated with dihydroartemisinin-piperaquine (DP), which will be administered once a day for three days.
- DP plus MB (Type: EXPERIMENTAL): Study participants in this arm will receive DP as described above combined with once-daily methylene blue (MB) for 3 days, at 15 mg/kg/day (45 mg/kg total over 3 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect on Cognitive Function of a Treatment With Aripiprazole

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Schizophrenia~* score of 2-6 in the CGI-S scale at basline~* ambulatory or hospitalized subjects having symptoms which requires antipsychotic treatment~Exclusion Criteria:~* women of child bearing potential~* women pregnant or breast feeding~* patients with a score of 0,-1 or 7~* substance use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Switch (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* positive Hepatitis B surface antigen (HBsAg) for \>6 months, positive HBeAg, HBV DNA \>500,000 copies/mL, and anti-HBs negative;~* liver disease consistent with Chronic Hepatitis B.~Exclusion Criteria:~* antiviral therapy for CHB within previous 6 months;~* co-infection with Hepatitis A virus (HAV), Hepatitis C virus (HCV), Hepatitis D virus (HDV) or Human immuno deficiency virus (HIV);~* evidence of decompensated liver disease;~* medical condition associated with chronic liver disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- peginterferon alfa-2a 90 μg_24 Weeks (Type: EXPERIMENTAL): Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.
- peginterferon alfa-2a 180 μg_24 Weeks (Type: EXPERIMENTAL): Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.
- peginterferon alfa-2a 90 μg_48 Weeks (Type: EXPERIMENTAL): Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.
- peginterferon alfa-2a 180 μg_48 Weeks (Type: EXPERIMENTAL): Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lifestyle and Pregnancy: The Clinical Effect of Lifestyle Intervention During Pregnancy in Obese Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* singleton pregnant~* BMI \>/= 30 and \</= 45~Exclusion Criteria:~* Chronic diseases~* Not Danish speaking~* Abuse of alcohol or drugs~* Preterm delivery in earlier pregnancies

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Lifestyle intervention (Type: EXPERIMENTAL): physical activity, dietetic counselling
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than or equal to 18 years of age.~* Patients with a mean seated systolic blood pressure (MSSBP) greater than or equal to 140 mmHg but less than or equal to 179 mmHg and a mean seated diastolic blood pressure (MSDBP) less than or equal to 109 mmHg following a 3 to 4-week single-blind placebo run-in period.~* The difference in MSSBP between Visits 3 and 4 or between Visits 4 and 4X must be less than or equal to 10 mmHg.~* Patients with a mean daytime (8AM-4PM) systolic blood pressure (SBP) greater than or equal to 135 mmHg and less than or equal to 179 mmHg and a mean daytime diastolic blood pressure (DBP) less than or equal to 109 mmHg as measured by an ambulatory blood pressure monitoring device (ABPM) following placebo run-in period.~* If female, must have negative serum pregnancy test at screening and be either post-menopausal (greater than or equal to 1 year), had a hysterectomy or tubal ligation at least 6 months before consent or if of childbearing potential, must practice approved measures of birth control throughout study.~Exclusion Criteria:~* History of stroke or transient ischemic attack (TIA) within the last one year.~* History of myocardial infarction, coronary angioplasty, coronary artery bypass graft, or heart failure within the past 6 months.~* Patients with secondary hypertension of any etiology, such as renal disease, pheochromocytoma, or Cushing's syndrome.~* Type I diabetes. Patients with Type II diabetes on stable treatment, with fasting glucose \<160 mg/dl may enroll.~* Patients with hemodynamically significant cardiac valvular disease.~* Patients with clinically significant cardiac conduction defects, including first, second or third degree AV block, left bundle branch block, sick sinus syndrome, atrial fibrillation, atrial flutter, an accessory bypass tract, or any arrhythmia requiring medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Olmesartan medoxomil, plus hydrochlorothiazide, if necessary
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets were taken once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete